Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment

Blood blood.2024027877.

https://doi.org/10.1182/blood.2024027877

Published: 2025

Includes: Supplemental data

Journal Articles

T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy

Blood blood.2025028833.

https://doi.org/10.1182/blood.2025028833

Published: 2025

Includes: Supplemental data

Journal Articles

Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Monica S. Nair, Sara K. Silbert, Kai Rejeski, Karilynn A. Wilson, Adam J. Lamble, Yannis Valtis, Bonnie Yates, Alexa Morales Arana, Roni Shouval, Kevin Curran, Rebecca A. Gardner, Haneen Shalabi, Colleen Annesley, Jae H. Park, Marion Subklewe, Nirali N. Shah

Blood (2025) 145 (11): 1136–1148.

https://doi.org/10.1182/blood.2024025910

Published: 2025

Includes: Supplemental data

Journal Articles

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Blood (2024) 144 (Supplement 1): 912.

https://doi.org/10.1182/blood-2024-203520

Published: 2024

Journal Articles

Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

Blood (2024) 144 (Supplement 1): 2034.

https://doi.org/10.1182/blood-2024-205548

Published: 2024

Journal Articles

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 471.

https://doi.org/10.1182/blood-2024-205809

Published: 2024

Journal Articles

Divergent Population Dynamics and Gene Signaling in Monocytes Distinctly Influence Responses to CD19-Targeted CAR T-Cells in Relapsed/Refractory B-NHL

Viktoria Blumenberg, Maryam Kazerani, Tobias Straub, Francesco Corrado, Vadim Borisov, Stephan Baumann, Galina Busch, Jan Wulf, Agnese Petrera, Kai Rejeski, Christian Schmidt, Benjamin Tast, Michael von Bergwelt-Baildon, Christoph Stein-Thöringer, Veit L. Buecklein, Marion Subklewe

Blood (2024) 144 (Supplement 1): 3425.

https://doi.org/10.1182/blood-2024-208938

Published: 2024

Journal Articles

Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 895.

https://doi.org/10.1182/blood-2024-208376

Published: 2024

Journal Articles

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Blood (2024) 144 (Supplement 1): 2369.

https://doi.org/10.1182/blood-2024-201029

Published: 2024

Journal Articles

Global Access to Chimeric Antigen Receptor (CAR) T-Cell Therapies: Health Technology Assessment (HTA) of CAR T in G7 Countries and Australia

Alex Y Ge, William B Feldman, Martin F Kaiser, Kai Rejeski, Gloria Iacoboni, Michael J Dickinson, Aaron S Kesselheim, Edward R Scheffer Cliff

Blood (2024) 144 (Supplement 1): 3659.

https://doi.org/10.1182/blood-2024-208943

Published: 2024

Journal Articles

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

Blood (2024) 144 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2024-203871

Published: 2024

Journal Articles

Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL

Blood (2024) 144 (Supplement 1): 1714.

https://doi.org/10.1182/blood-2024-211459

Published: 2024

Journal Articles

Predictive Value of Maximum Tumor Dissemination (Dmax) in Lymphoma Patients Treated with CD19 Specific CAR T-Cell Therapy

Wolfgang G Kunz, Viktoria Blumenberg, Kai Rejeski, Gabriel Sheik, Matthias Brendel, Michael Von Bergwelt, Marion Subklewe, Michael Winkelmann

Blood (2024) 144 (Supplement 1): 6552.

https://doi.org/10.1182/blood-2024-209594

Published: 2024

Journal Articles

Secondary Hematologic Malignancies in Patients Following Chimeric Antigen Receptor T-Cell Therapy: Aggregated Clinical Trial Data from 1542 Patients

Edward R Scheffer Cliff, Penelope Lafeuille, Sheila Diamond, Jacob Aptekar, David A Russler-Germain, Kai Rejeski, Aaron S Kesselheim

Blood (2024) 144 (Supplement 1): 2077.

https://doi.org/10.1182/blood-2024-203979

Published: 2024

Journal Articles

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Jaime Roman Diaz, Saurabh Dahiya, Francesca Emily Sillito, Maeve O'Reilly, Kai Rejeski, Veit L. Buecklein, Marion Subklewe, Gloria Iacoboni, Pere Barba, Claire Roddie, Frederick Locke, Jay Y. Spiegel, Najla H. Al Ali, Zachary Thompson, Jongphil Kim, Rami S. Komrokji, Michael D. Jain

Blood (2024) 144 (Supplement 1): 7239.

https://doi.org/10.1182/blood-2024-201666

Published: 2024

Journal Articles

Evaluation of the Individual Components of the International Metabolic Prognostic Index (IMPI) in the Context of CAR T-Cell Treatment of Lymphoma

Michael Winkelmann, Kai Rejeski, Viktoria Blumenberg, Gabriel Sheikh, Veit L. Buecklein, Matthias Brendel, Michael Von Bergwelt, Marion Subklewe, Wolfgang G Kunz

Blood (2024) 144 (Supplement 1): 7508.

https://doi.org/10.1182/blood-2024-207418

Published: 2024

Journal Articles

Infections Drive Non-Relapse Mortality Following CAR-T Therapy across Disease Entities and CAR Products - a Meta-Analysis of Clinical Trials and Real-World Studies

David M. Cordas dos Santos, Tobias Tix, Kai Rejeski

Blood (2023) 142 (Supplement 1): 1064.

https://doi.org/10.1182/blood-2023-187516

Published: 2023

Journal Articles

Phenotypic, Transcriptomic and Proteomic Characteristics of CAR T-Cell Dysfunction Are Associated with Inferior CAR T-Cell Expansion and Treatment Failure in r/r B-NHL

Viktoria Blumenberg, Maryam Kazerani, Stephan Baumann, Tobias Straub, Francesco Corrado, Jan Wulf, Galina Busch, Kai Rejeski, Lisa Frölich, Christian Schmidt, Michael von Bergwelt-Baildon, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 3439.

https://doi.org/10.1182/blood-2023-187495

Published: 2023

Journal Articles

Distinct Temporal Dynamic Serum Metabolite Profiles Characterize Treatment Response and Early Toxicity after B-Cell Lymphoma Directed CAR-T-Cell Therapy

David M. Cordas dos Santos, Amar Hadzic, Martin E. Kirmaier, Werner Schmitz, Viktoria Blumenberg, Kai Rejeski, Veit L. Buecklein, Michael von Bergwelt-Baildon, Marion Subklewe, Sebastian Theurich

Blood (2023) 142 (Supplement 1): 2078.

https://doi.org/10.1182/blood-2023-186178

Published: 2023

Journal Articles

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Blood (2023) 142 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2023-182415

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment

T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy

Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Divergent Population Dynamics and Gene Signaling in Monocytes Distinctly Influence Responses to CD19-Targeted CAR T-Cells in Relapsed/Refractory B-NHL

Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Global Access to Chimeric Antigen Receptor (CAR) T-Cell Therapies: Health Technology Assessment (HTA) of CAR T in G7 Countries and Australia

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL

Predictive Value of Maximum Tumor Dissemination (Dmax) in Lymphoma Patients Treated with CD19 Specific CAR T-Cell Therapy

Secondary Hematologic Malignancies in Patients Following Chimeric Antigen Receptor T-Cell Therapy: Aggregated Clinical Trial Data from 1542 Patients

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Evaluation of the Individual Components of the International Metabolic Prognostic Index (IMPI) in the Context of CAR T-Cell Treatment of Lymphoma

Infections Drive Non-Relapse Mortality Following CAR-T Therapy across Disease Entities and CAR Products - a Meta-Analysis of Clinical Trials and Real-World Studies

Phenotypic, Transcriptomic and Proteomic Characteristics of CAR T-Cell Dysfunction Are Associated with Inferior CAR T-Cell Expansion and Treatment Failure in r/r B-NHL

Distinct Temporal Dynamic Serum Metabolite Profiles Characterize Treatment Response and Early Toxicity after B-Cell Lymphoma Directed CAR-T-Cell Therapy

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only